Epoetin alfa biosimilar (Sandoz)

阿法依伯汀生物类似药（山德士）

Report date: 2026/05/26 20:00:28

Base Information

Drug NameEpoetin alfa biosimilar (Sandoz)
Drug Alias Name重组人红细胞生成素生物仿制药（山德士）HX 575 epoetin alfa阿法依伯汀生物仿制药（山德士）Epoetin lambdaGrandicrit +[14] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionErythropoiesis stimulantsErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemiaKidney Failure, ChronicRenal Insufficiency, Chronic
Global Approved IndicationsAnemiaKidney Failure, Chronic
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2007/08/27
Country/TerritoryBulgariaUkrainePoland +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSandoz
China Registration ClassN/A

Develop Information

Active CompaniesHexal Ag
Inactive CompaniesSandoz
Active IndicationsAnemiaKidney Failure, Chronic
Inactive IndicationsRenal Insufficiency, Chronic

Other Information

ATC CodeB03XA01
Related LinksN/A